Abstract: New uses of a triple agonist are disclosed. A triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, or conjugates thereof exhibits an activity of preventing and/or treating lung diseases. A use of the triple agonist or a conjugate thereof as a preventive and/or therapeutic agent for lung disease, and compositions and methods for preventing and/or treating lung cancer employing the triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, and/or conjugates are disclosed.
Type:
Application
Filed:
November 20, 2020
Publication date:
April 20, 2023
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Seon Myeong LEE, Jong Suk LEE, Jung Kuk KIM, Sang Hyun LEE, Euh Lim OH, Hyo Sang JO, Eun Jin PARK, Chong Yoon LIM
Abstract: The present invention relates to a crystalline form of a phenyl carbamate derivative compound and a use thereof, and more particularly, to a more thermodynamically stable crystal, i.e., a Pattern 1 crystalline form, and a preparation method thereof. Amorphous and crystalline forms were prepared using various solvents, and among these, a thermodynamically stable Pattern 1 crystalline form and a pharmaceutical use of this crystalline form are provided.
Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. The GLP-2 derivative or a conjugate thereof are useful in preventing or treating one or more diseases selected from intestinal disease, intestinal injury, or gastrosia. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.
Type:
Application
Filed:
November 2, 2022
Publication date:
March 23, 2023
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jaehyuk CHOI, Min Young KIM, In Young CHOI, Sung Youb JUNG
Abstract: The present invention provides a method for preparing a pyrrolopyrimidine compound and application thereof. Specifically, the present invention provides a compound represented by formula I or pharmaceutically-acceptable salts thereof, a pharmaceutical composition containing the compound or its salts, and a method for preparing the pharmaceutical composition and an application of the pharmaceutical composition as an immunosuppressive drug.
Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
February 28, 2023
Assignee:
BEIJING HANMI PHARM. CO., LTD.
Inventors:
Jiawang Liu, Nanmeng Song, Yaping Yang, Mengxie Jin
Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
Type:
Grant
Filed:
January 15, 2021
Date of Patent:
February 28, 2023
Assignee:
GEISTLICH PHARM A AG
Inventors:
Rolf W. Pfirrmann, Hanns Moehler, Thomas Mueller
Abstract: An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.
Type:
Application
Filed:
January 22, 2021
Publication date:
February 23, 2023
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Bo Sik KIM, Hyuk Jun CHO, Ho Taek IM, Yong II KIM
Abstract: The present disclosure relates to a method for delivering a mucoadhesive composition to the oral cavity of a subject. The mucoadhesive composition comprises one or more active agents, a mucoadhesive polymer, and water. The present disclosure is further related to a method for treating a disease, disorder, or condition, such as pharyngitis, aphthous stomatitis (canker sore), bacterial infection, radiation-induced mucositis, fibromyalgia, and diabetes, comprising administering the mucoadhesive composition to the oral cavity of a subject. The present disclosure is also related a mucoadhesive composition comprising one or more active agents, a mucoadhesive polymer, and water.
Abstract: A composition containing a glucagon derivative and a GLP-1 and GIP receptor dual agonist, and uses thereof are disclosed. The glucagon derivative comprises an amino acid sequence of the formula 1: X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-WL-X27-X28-X29-X30 (Formula 1). The composition is useful in preventing or treating metabolic syndrome.
Type:
Application
Filed:
October 5, 2020
Publication date:
January 5, 2023
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jung Kuk KIM, Jong Suk LEE, A Ram LEE, Joo Young DONG
Abstract: This present invention relates to a drug carrier comprising a polymer of ?-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal, and a method for preparing the same. It can have a long circulation time in the blood, and can realize a charge reversal from negatively charged or the neutral to positively charged around the tumor blood vessel region, so that the positively charged polymer effectively penetrates deep into the tumor tissue, fast entering into the tumor cells, and greatly improves the therapeutic effect of the drug on the tumor. This overcomes the problems of slow diffusion of traditional polymer drug carriers in tumors and weak interaction with tumor cells, and has great significance in the field of anticancer treatment in the medical field.
Type:
Grant
Filed:
May 6, 2022
Date of Patent:
December 27, 2022
Assignee:
Hainan Poly Pharm Co., Ltd.
Inventors:
Youqing Shen, Quan Zhou, Changhuo Xu, Jiajia Xiang
Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.
Type:
Grant
Filed:
March 27, 2020
Date of Patent:
December 20, 2022
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Jaehyuk Choi, Min Young Kim, In Young Choi, Sung Youb Jung
Abstract: The present invention relates to a pharmaceutical preparation comprising a granule comprising a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a diluent. The pharmaceutical preparation has a high productivity of the preparation due to excellent tableting properties, friability, and mass uniformity. The pharmaceutical preparation has low generated amount of impurities and high stability.
Type:
Application
Filed:
October 23, 2020
Publication date:
December 1, 2022
Applicant:
Hanmi Pharm Co., Ltd.
Inventors:
Young II Kim, Taek Kwan Kwon, Ho Taek Im, Yong II Kim
Abstract: A physiologically active polypeptide-immunoglobulin Fc fragment conjugate and a method for making the conjugate are disclosed. The conjugate contains a physiologically active polypeptide linked via a non-peptidyl linker to an immunoglobulin Fc fragment having an FcRn-binding region and maintains the intrinsic binding affinity of the immunoglobulin Fc fragment. A method of maintaining the intrinsic binding affinity of the conjugate for FcRn, and a composition containing the conjugate, which maintains the intrinsic binding affinity of the immunoglobulin Fc fragment for FcRn are also disclosed.
Type:
Application
Filed:
August 3, 2022
Publication date:
December 1, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Sang Youn HWANG, Jong Soo Lee, Sung Hee Hong, In Young Choi, Sung Youb Jung, Se Chang Kwon
Abstract: Composition including GLP-2 or a long-acting conjugate thereof and uses thereof are disclosed. The composition including GLP-2 or a long-acting conjugate thereof is useful for preventing or treating metabolic bone diseases.
Type:
Application
Filed:
December 24, 2020
Publication date:
November 17, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jae Hyuk CHOI, Jin Bong LEE, Sang Hyun LEE, Sang Don LEE, Min Young KIM
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, comprising snake venom derived from Agkistrodon piscivorus piscivorus or Naja melanoleuca, which are types of snakes, an extract thereof, or a fraction thereof; a quasi-drug composition; a food composition; a cosmetic composition; and a method of treating rheumatoid arthritis by using the composition. The snake venom derived from Agkistrodon piscivorus piscivorus or Naja melanoleuca of the present invention can improve, alleviate, or treat symptoms of rheumatoid arthritis, which is a kind of autoimmune diseases, and thus will be able to be widely used in the development of therapeutic agents for various autoimmune diseases including rheumatoid arthritis.
Abstract: The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
November 8, 2022
Assignee:
Hanmi Pharm. Co., Ltd.
Inventors:
In Hwan Bae, Seung Hyun Jung, Young Gil Ahn, Kwee Hyun Suh
Abstract: The present invention relates to a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an effective ingredient for prevention or treatment of prostate cancer. THA in the present invention is a main ingredient of Curcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.